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Abstract 
Background: We provide an overview of the genetic 
architecture of quantitative cardiovascular phenotypes 
such as blood pressure (BP), electrocardiogram (ECG) 
and cardiac imaging measurements which play a critical 
and prognostic role in the management of numerous 
diseases. 
Methods: The genetics of BP, ECG and cardiac imaging 
traits have been studied in large-scale genome-wide 
association studies (GWASs). 
Results: To-date more than 1,400 BP loci have been 
discovered. These genetic loci harbouring known and 
novel BP-regulating genes, several of which are linked to 
existing drugs, that can be repurposed for BP treatment. 
Regarding the ECG indices, 437 independent signals have 
been reported for resting heart rate (n ~ 400,000), mainly 
modulating the autonomic nervous system, as well as 202 
loci for PR interval, 29 loci for QRS duration and 35 loci 
for QT interval. The LV GWASs (n ~ 17,000) identified 14 
loci harbouring genes regulating the cardiac 
developmental pathways. 
Conclusion: Large-scale genetic analyses of 
quantitative cardiovascular traits have yielded hundreds 
of susceptibility loci, candidate genes and key biological 
pathways, which significantly advance our understanding 
of their genetic architecture and shed lights on potential 




Quantitative measurements such as blood pressure (BP) 
and electrocardiogram (ECG) and cardiac imaging 
parameters play a dominant role in the assessment of 
cardiovascular (CV) health. They are important 
endophenotypes which represent a wide spectrum of 
variation reflecting normal physiology to an overt 
pathology. Hypertension, diagnosed by the presence of 
elevated systolic and/or diastolic blood pressure (SBP and 
DBP), is the most important modifiable risk factor 
attributable to 10.4 million deaths worldwide in 2017 (1). 
Abnormalities in cardiac electrical phenotypes derived 
from ECG, such as PR interval and QT interval, are 
predictive of future risk of arrhythmia and sudden death 
(2,3). Lastly, cardiac imaging technologies such as 
echocardiography (ECHO) and cardiovascular magnetic 
resonance (CMR) provide a plethora of measurements 
related to cardiac structure and function, instrumental in 
the management of many CV diseases. All of these 
phenotypes are the so-called common and complex traits 
under the influence of genes, environment and their 
intricate interplay. Typically, the genetic basis of such 
phenotypes is investigated with genome-wide association 
studies (GWASs). Here, we provide a brief overview of 
key findings from the published GWASs which illuminates 
the genetic architecture of clinically relevant quantitative 
CV traits. 
 
2. Genome-wide association studies 
At the turn of 21st century, the human genome project 
completed sequencing of the entire human genome 
consisting of 3 billion nucleotide base pairs at a cost of ~2.7 
billion US dollars. Since then, the genotyping cost has 
fallen exponentially, bringing the genomic technology to 
the masses. Over the last decade, several population-based 
studies had conducted whole-genome genotyping – most 
commonly with DNA micro-arrays – in thousands to 
millions of individuals. Although the human genome is 
99.9% identical between individuals, each person’s genome 
differs from the reference human genome at 4 to 5 million 
sites, the majority of which are single nucleotide 
polymorphisms (SNPs). GWASs systematically examines 
these genetic variations across the genome, in order to 
identify regions (loci) associated with a particular trait or 
disease. They provide an important avenue to agnostically 
evaluate the association between human genetic variations 
and complex traits and are well-suited to investigate the 
genetic determinants of both quantitative traits and binary 
disease status. Downstream utilities of GWAS results 
include: (i) estimation of heritability to understand the 
genetic architecture of a trait; (ii) examination of genetic 
correlations which detect and quantify pleiotropy; (iii) 
identification of candidate causal genes which explain the 
biology and may lead to novel therapies and drug 
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repurposing opportunities; (iv) construction of polygenic 
risk scores; and (v) creation of genetic instruments for 
Mendelian randomisation studies to explore causal 
relationships. 
 
2.1. Genomic studies of blood pressure 
traits 
Hypertension is an important root cause of stroke, 
coronary artery disease, heart failure and kidney disease. 
Given its clinical importance and the simplicity of data 
acquisition, BP is perhaps the most well-studied 
quantitative CV trait with a large genomic knowledge base. 
The discovery of genetic loci associated with BP traits is 
further aided by the emergence mega studies and consortia 
such as the UK Biobank (n ~ 500,000) (4), the US Million 
Veteran Program (n ∼ 318,891) (5) and the International 
Consortium of Blood Pressure (ICBP) (n ~ 299,024) (6). 
BP is highly heritable with 20 – 50% of variability 
attributable to genetics (7). However, even a very large 
recent study in over a million individuals only recovered 
27% of expected heritability (8), highlighting the 
magnitude of gap in our knowledge. To date, a total of 
1477 BP risk loci have been reported in the literature, 
consistent with the polygenicity of BP regulation which 
creates a significant challenge in disentangling the 
biological function of each locus. Increasingly, in-silico 
analyses leveraged on publicly available genomic 
databases are used to prioritise candidate genes which can 
be followed up in experimental studies using techniques 
like CRISPR gene editing. This approach has highlighted 
a number of highly promising genes that led to an 
improved understanding of BP physiology and drug 
repurposing. An example of such success story is the 
UMOD (uromodulin) gene identified in an early BP 
GWAS (9). Hypertensive individuals with AA genotype at 
rs13333226 variant have higher UMOD excretion, greater 
salt sensitivity and greater BP drop in response to loop 
diuretics when compared with those with GG genotype (9). 
This observation alongside other supporting evidence in a 
transgenic mouse model (10) has resulted in a phase-4 
clinical trial that investigates if the therapeutic response of 
a known antihypertensive agent (Torasemide) differs 
depending on the genotype (AA vs AG/GG) 
(https://clinicaltrials.gov/ct2/show/NCT03354897). The 
abundance of candidate BP genes allows the enrichment 
(also known as over-representation) analysis which 
highlights key biological pathways (11). Some notable 
pathways include G-protein coupled receptor signalling, 
extracellular matrix regulation and olfactory signalling 
which can be dissected in future studies for potential 
therapeutic targets. 
 
2.2. Genomic studies of ECG traits 
Before the advent of GWASs, the genetic underpinning 
of cardiac electrical activity was primarily investigated in 
the context of Mendelian channelopathies such as the long 
QT syndrome (LQTS). Inclusion of ECG in more recent 
large-scale population genomic studies enabled 
investigations into the genetic basis of prognostically 
important ECG-derived electrical traits. Observationally, 
elevated resting HR is associated with an increased risk of 
CV morbidity and mortality (12). A recent GWAS of 
resting HR in the UK Biobank (n = 428,250) discovered a 
total of 437 genetic loci (13) and evidence of genetic and 
causal association between resting HR and type 2 diabetes. 
The analysis of shared genes between the two traits 
highlighted the role of glucose homeostasis, energy 
metabolism and autonomic activity which may explain the 
co-existence high resting heart rate and type 2 diabetes. A 
multi-ancestry GWAS of PR interval, a conduction trait, 
reported 202 loci (141 of which were novel) enriched in 
cardiac muscle development and cytoskeletal genes (14). 
The polygenic risk score of PR interval is predictive of 
atrial fibrillation (AF) and distal conduction disease, 
recapitulating the findings from prior observational 
studies. As for QRS duration which represents ventricular 
depolarisation and conduction, a total of 29 loci have been 
reported to date by studies in a diverse set of ethnicities 
(15,16). Interestingly, PR-associated MYOCD locus 
containing MYOCD gene that plays a role in cardiogenesis 
was discovered only in Hispanic individuals underlining 
the importance of expanding the genome-wide discovery 
analysis into non-European ancestries (15). The QT 
interval which reflects myocardial repolarisation is a key 
measurement for the diagnosis of Mendelian long and 
short QT syndromes and can be modulated by electrolyte 
imbalance, myocardial ischaemia and medications. QT 
prolongation has been associated with malignant 
arrhythmias and sudden cardiac death (17). A large 
genome-wide association meta-analysis (n ~ 103,331) of 
QT interval yielded a total of 35 genome-wide significant 
loci which harbour not only known genes implicated in 
LQTS, but novel genes such as ATP2A2, PLN, PRKCA, 
SRL and SLC8A1 that modulate the calcium signalling 
pathway (18). A more refined assessment of repolarisation, 
namely T-peak-to-T-end-interval (Tpe), has been 
investigated in a GWAS which identified 32 loci 
comprising genes involved in cellular processes of 
ventricular repolarisation (19). More recently, several 
studies have looked into exercise ECG measurements 
which are known to be prognostically important. A GWAS 
of HR response to exercise and recovery discovered 30 loci 
containing genes involved in neural development and 
regulation of autonomic nervous system (20). Another 
study on exercise QT dynamics revealed 20 loci 
comprising genes implicated in LQTS, mitochondrial 
calcium handling and autonomic regulation (21). A 
genome-wide investigation into exercise-related variation 
in the T-wave morphology, known as T-wave morphology 
Page 2
restitution (TMR), identified 12 loci and the polygenic risk 
score developed from the loci of exercise-recovery TMR 
was predictive of future CV events (22). 
 
2.3. Genomic studies of cardiac imaging 
traits 
Cardiac imaging phenotypes mediate considerably 
heterogeneous syndromes such as heart failure and 
inherited cardiomyopathies. They can be measured with a 
high precision using current imaging techniques. In 
particular, ECHO and CMR are well-suited for large-scale 
population studies due to their non-ionising properties. 
Imaging phenotypes can be objectively quantified and 
evaluated as indicators of both normal biological and 
pathogenic processes. They may be superior to binary 
disease traits such as heart failure in a GWAS due to their 
ability to detect pre-clinical changes with a diminished 
misclassification bias. The largest published GWAS of 
ECHO-derived measurements (16 left ventricular [LV] 
and aortic phenotypes) conducted in 46,533 European 
individuals discovered 12 loci for aortic diameter, 3 loci 
for LV end-diastolic diameter, one locus each for LV 
fractional shortening, LV mass and peak velocity of mitral 
valve inflow corresponding to atrial contraction (Mv-A) 
(23). Another ECHO-based study in Japanese individuals 
(n max ~ 19000) reported a total of 14 novel loci: 2 loci for 
LV end-diastolic diameter, 3 loci for LV ejection fraction, 
4 loci each for LV end-systolic diameter and LV fractional 
shortening and one locus for LV relative wall thickness 
(24). Limited follow-up data are available for these GWAS 
signals. Of note, the MTSS1 locus for LV end-diastolic 
diameter, identified by both European and Japanese studies 
contains MTSS1 gene which is expressed in the heart and 
encodes a scaffold protein that regulates actin dynamics 
(25). A more recent study of LV phenotypes (n ~ 17000) 
using CMR, which leveraged on the breakthroughs in 
automatic segmentation by deep learning, discovered 14 
locus-phenotype associations of which 6 loci were novel 
for LV imaging traits (26). Some noteworthy candidate 
genes in these loci include: TTN involved in sarcomere 
assembly and stretch sensing with its truncating variants 
found to be causal in 10% to 20% of dilated 
cardiomyopathy (DCM) cases (27); BAG3 (associated with 
LV end-systolic volume and LV ejection fraction) essential 
for Z-disc integrity and also implicated in DCM (28); 
ALPK3 that regulates cardiomyocyte differentiation (29), 
and MMP11 involved in extracellular matrix homeostasis 
(30). Polygenic risk scores constructed from the LV 
GWASs were predictive of incident heart failure 
supporting the role of imaging phenotypes (specifically, 





Significant progress has been made in unravelling the 
genetic underpinning of quantitative cardiovascular 
phenotypes based on the large-scale GWASs of common 
variants. The time is upon us to capitalise on the gain in 
knowledge by conducting mechanistic studies of the 
promising candidate genes which may lead to novel 
therapies. Delving into the rare variants aided by the 
emerging data from whole genome sequencing may shine 
the light on the hitherto missing heritability and potentially 
identify new variants with larger effect sizes. Certain 
genetic loci demonstrated pleiotropic associations with 
multiple cardiovascular traits (for instance, SH2B3 locus 
with BP and LV end-diastolic volume; TTN with multiple 
imaging traits, PR interval and AF). This observation 
underlines their intricate physiological and mechano-
electrical relationships which could be exploited by joint 
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